DIRECT ANTIGLOBULIN TESTING OF PATIENTS WITH MULTIPLE MYELOMA TREATED WITH ANTI-CD38 MONOCLONAL ANTIBODIES

DOI Web Site 15 References
  • Hosokawa Mika
    Department of Blood Transfusion, Osaka University Hospital
  • Nagamine Keisuke
    Department of Blood Transfusion, Osaka University Hospital
  • Aochi Hiroshi
    Department of Blood Transfusion, Osaka University Hospital
  • Nakayama Kotarosumitomo
    Department of Blood Transfusion, Osaka University Hospital
  • Sakuragi Mikiko
    Department of Blood Transfusion, Osaka University Hospital
  • Morikawa Tamayo
    Department of Blood Transfusion, Osaka University Hospital
  • Nakao Mayumi
    Department of Blood Transfusion, Osaka University Hospital
  • Kiyokawa Tomoko
    Department of Blood Transfusion, Osaka University Hospital
  • Kato Hisashi
    Department of Hematology and Oncology, Graduate School of Medicine, Osaka University
  • Tomiyama Yoshiaki
    Department of Blood Transfusion, Osaka University Hospital Uegahara Hospital
  • Kashiwagi Hirokazu
    Department of Blood Transfusion, Osaka University Hospital Department of Hematology and Oncology, Graduate School of Medicine, Osaka University

Bibliographic Information

Other Title
  • 多発性骨髄腫患者に対する抗CD38モノクローナル抗体製剤投与が直接抗グロブリン試験に与える影響

Search this article

Abstract

<p>Daratumumab and Isatuximab are humanized IgG monoclonal antibodies (MoAbs) which target CD38. Administration results in a positive indirect antiglobulin test because erythrocytes express CD38. However, effects on the direct antiglobulin test (DAT) are unclear. We investigated DAT in 17 patients with multiple myeloma (MM) treated with these MoAbs. Tube-DAT was negative in 15 cases before administration (Pre). Nine turned positive on Day 1 after administration, and became negative again on Days 6-8. CAT-DAT was positive in 8 and 15 cases on Pre and Day 1, respectively, and all 7 cases who turned positive on Day 1 became negative again on Days 6-8. The amount of IgG bound on erythrocytes increased on Day 1 in 16 cases, and returned to near the Pre level on Days 6-8. CD38 expression on erythrocytes decreased by ~70% and ~90% on Day 1 and Days 6-8, respectively, and it is highly likely that a severe reduction in CD38 expression lead to a loss of DAT positivity on Days 6-8. Hemoglobin level decreased by 8.7% on Day 1. Low-concentration DTT treatment showed that most of the positive DAT results on Days 6-8 were caused by non-specific IgG binding. DAT of MM patients after anti-CD38 MoAb administration should be carefully interpreted, because it is affected by a reduction in CD38 expression and non-specific IgG binding.</p>

Journal

References(15)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top